Dupixent Strength Lifts Sanofi’s Outlook

Sanofi’s third-quarter performance shows that Dupixent remains the principal engine of near-term growth, with the immunology drug’s strong sales and momentum across newer launches supporting a higher 2026 outlook. The central question for the pharmaceutical business is no longer whether demand is holding up, but whether Sanofi can broaden that momentum enough as Dupixent approaches loss of exclusivity.

Dupixent drives the earnings surprise

Sanofi reported third-quarter revenue of €14.44 billion, up 16.2% year over year and €1.12 billion above expectations. Dupixent sales increased 34.8% to €5.7 billion, exceeding the €5.2 billion forecast and rising above €5 billion in a quarter for the second time.

That performance was central to the company’s “Business” earnings per share, a non-GAAP measure that excludes one-off charges. Business EPS grew 22% year over year to €3.55, above the €2.79 estimate cited by Investing.com. The revenue and earnings figures show that Dupixent’s growth was sufficient to lift performance beyond expectations despite weakness elsewhere in the portfolio.

Guidance rise confirms broader portfolio momentum

Sanofi increased its full-year 2026 outlook to low-teens percentage sales growth at constant exchange rates, up from the previously forecast 10%. It now projects mid-teens percentage growth in Business EPS at constant exchange rates, replacing guidance for Business EPS to grow slightly faster than sales.

The upgrade was not driven solely by Dupixent. Sales from pharmaceutical launches rose 31.4% to €1.4 billion, with reported contributions from ALTUVIIIO, Ayvakit and Rezurock. This gives the company a second source of growth alongside its established immunology franchise, although the available results do not quantify each product’s individual contribution or establish the breadth of the portfolio beyond those named launches.

Vaccines show the remaining offset

Vaccine sales declined 6.6% to €3.2 billion, which the reporting attributed to anticipated phasing in respiratory prevention. The contrast with Dupixent and the launch portfolio illustrates the uneven composition of Sanofi’s growth: immunology and newer medicines are expanding rapidly, while vaccine timing continues to affect quarterly performance.

The company’s own guidance indicates that the latest quarter gives it enough confidence to raise the full-year sales outlook. Dupixent’s €5.7 billion quarterly contribution also makes the franchise’s approaching loss of exclusivity a material future issue. Sanofi CEO Belén Garijo said the organization was focused on managing its post-Dupixent trajectory over the next decade and protecting earnings through the drug’s loss of exclusivity.

Growth concentration remains the key test

The earnings result supports a favorable near-term assessment of Sanofi, but it also exposes concentration risk: Dupixent accounted for roughly two-fifths of reported quarterly revenue, while vaccine sales contracted. A precise calculation from the rounded figures would be misleading, but the scale of Dupixent’s contribution is clear.

The relevant industry signal is therefore mixed but constructive. Current demand for Dupixent remains strong, and the launch portfolio is adding meaningful growth that helped Sanofi raise guidance. The longer-term performance test is whether new products can increasingly offset Dupixent as its exclusivity period ends. The reviewed reporting does not provide a specific sales target or timetable for that transition.

The next observable milestone is the continued progression of Dupixent and the named launches against Sanofi’s upgraded full-year guidance. No procurement opportunity or supplier signal was disclosed in the reviewed reporting.

Industry and product implications